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A B S T R A C T
Mutations in the SCN1A gene can cause a variety of dominantly inherited epilepsy syndromes. Severe
phenotypes usually result from loss of function mutations, whereas missense mutations cause a milder
phenotype by altering the sodium channel activity. We report on a novel missense variant
(p.Val1379Leu) in the SCN1A gene segregating in an autosomal dominant pattern in a family exhibiting
a variable epilepsy phenotype ranging from generalized epilepsy with febrile seizures during infancy to a
well controlled seizure disorder in adulthood. This report supports the importance of SCN1A mutation
analysis in families in which seizure disorders segregate in an autosomal dominant fashion.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Mutations in the SCN1A gene encoding voltage-gated sodium
channels cause a variety of dominantly inherited epilepsy
syndromes including generalized epilepsy with febrile seizures
plus (GEFS+) and severe myoclonic epilepsy of infancy (SMEI).1,2
Most mutations that cause GEFS+ are missense and are presumed
to result in a milder phenotype by altering the sodium channel
activity, whereas mutations associated with SMEI result in loss of
function of the channel.1,3 Given that a loss of function mutation
can sometimes be associated with a milder phenotype, mutation
type cannot reliably predict a severe outcome.4 We report on a
novel variant in the SCN1A gene segregating dominantly with a
variable epilepsy phenotype.
2. Methods and case studies
2.1. Presentation of the propositus
The propositus presented at nine months of age with focal seizures
with secondary generalization lasting for 15 min. He had a two day
history of rhinorrhea and fever. The seizures stopped with the use of
diazepam and the infant was discharged without anti-epileptic
medications. He presented again at eleven months of age with
twitching of his left arm that progressed to generalized tonic clonic
seizures that lasted for 10 min. He had been previously well and had
not been febrile. An EEG revealed sharp waves localized to the left* Corresponding author. Tel.: +1 204 787 2958; fax: +1 204 787 1419.
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placed on phenobarbital, but due to the development of a rash,
phenobarbital was stopped and he was started on clobazam. An EEG at
twenty-ﬁve months of age revealed generalized bursts of spike and
slow wave activity and rare left frontal sharp waves. At twenty-seven
months of age he presented with a cluster of four generalized seizures.
He was febrile with a two day history of an upper respiratory tract
infection. Treatment with valproic acid was started and clobazam was
discontinued. However, the patient developed thrombocytopenia
necessitating the discontinuation  of valproic acid and the initiation of
treatment with keppra. As seizure control was poor, treatment was
changed to stiripentol plus clobazam yielding an excellent clinical
response. A repeat EEG at thirty months of age was normal.
2.2. Family history
Our patient was the ﬁrst born to a nineteen year-old mother of
Cambodian descent and a twenty-ﬁve year-old father of Filipino
descent. The pregnancy, perinatal and neonatal histories were
unremarkable. The parents are not consanguineous. There was a
family history of seizures in the patient’s mother, one of his
maternal aunts, and one of her sons (Fig. 1). The mother suffered
from tonic clonic seizures since four years of age which continue to
be well-controlled with valproic acid treatment. The maternal aunt
has had grand mal seizures since infancy. She has been seizure free
since treatment with valproic acid was initiated at twelve years of
age. During the maternal aunt’s two pregnancies, seizure control
worsened after switching her to carbamazepine. Her oldest son is
healthy while her youngest son experienced febrile seizures at six
months of age. The other maternal aunt and the maternal uncle
have no history of seizures.vier Ltd. All rights reserved.
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Fig. 1. The family pedigree and the results of the SCN1A mutation analysis.
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On examination at thirty-six months of age the propositus
appeared to have no dysmorphic features. His growth parameters
revealed a weight of 16.4 kg (50th–75th percentile), a height of
98 cm (25th percentile) and an OFC of 49.3 cm (25th–50th
percentile). His systemic examination was unremarkable. At
thirty-eight months of age his gross motor skills were age
appropriate, his ﬁne motor skills were at a thirty month level
and his language skills were delayed at a twenty-four month level.
2.4. Investigations and diagnostic process
An extensive work-up was initiated to investigate the cause of his
seizures and developmental delay. These included a brain MRI scan,
capillary and CSF lactate, plasma amino acids, urine organic acids,
urine succinylpurine, urine thiosulfate, biotinidase enzyme assay,
plasma acylcarnitine proﬁle, CSF protein, amino acids and glucose
and a chromosome analysis. These investigations were normal.
Based on the child’s history of febrile and generalized seizures
and the signiﬁcant family history, a diagnosis of generalized
epilepsy with febrile seizures plus (GEFS+) was entertained and
sequencing of the SCN1A gene was initiated. Using genomic DNA
obtained from whole blood, the 26 amplicons of the SCN1A gene
were ampliﬁed and scanned by dHPLC for heterozygous mutations.
Bidirectional sequence analysis was used to conﬁrm any positive
ﬁndings by the dHPLC analysis. A previously unreported unknown
variant, c.4135G > T, which leads to the missense mutation,
p.Val1379Leu, was detected in the pore region of the SCN1A gene
(NM_006920.4). To further elucidate the potential pathogenicity of
this variant, blood samples were obtained from all available family
members; both those who have had seizures and those who were
unaffected (Fig. 1). The mother and the affected maternal ﬁrst
cousin were found to be heterozygous for this p.Val1379Leu
variant. The affected maternal ﬁrst cousin’s mother is inferred to be
an obligate carrier. Unaffected family members including the
maternal aunt, the maternal uncle and a maternal ﬁrst cousin did
not carry this speciﬁc variant. The maternal grandparents were
unavailable for testing and their medical histories were unknown.
3. Discussion
Generalized epilepsy with febrile seizures plus (GEFS+) is
characterized by an autosomal dominant mode of inheritance withvariable expressivity and incomplete penetrance.2,3,5 Although
the range of severity in this type of SCN1A related disorder is wide,
in general the seizure phenotypes in affected families tend to be
mild.2 The more severe seizure types are thought to be associated
with reproductive disadvantage and hence are less likely to be
recognized as familial.6 Affected individuals within a family with
GEFS+ often present with febrile seizures (FS) in early childhood
followed by occasional tonic, clonic, myoclonic, or absence
seizures which respond to medication and remit by late childhood
or early adolescence. Our family’s presentation is consistent with
this phenotype. The two sisters who had generalized seizures
from early infancy have a relatively mild phenotype with good
control on monotherapy especially in later adolescence. It is
noteworthy that the maternal aunt’s seizures worsened during
her pregnancies following changing her medication from valproic
acid to carbamazepine. Liao et al.,7 reported that mutations in the
pore region of the SCN1A gene cause loss-of-function or partial
loss-of-function of the sodium channel. This may explain why
sodium channel blocker antiepileptic medications, including
carbemazepine, may cause seizure control to worsen, as experi-
enced by our patient.7
Three affected family members from two generations were
found to be heterozygous for this variant. The affected maternal
aunt was inferred to be an obligate carrier. The three unaffected
family members who were available for testing did not carry this
variant. Based on segregation analysis, the likelihood of this
variant co-segregating with the seizure disorder phenotype is
1000–1. It is possible that there are other explanations for the
ﬁndings in this family and perhaps another undetected mutation
closely linked to the variant is responsible for the phenotype.
However, it is compelling to note that the valine at codon 1379 is
highly conserved across the animal species including rhesus
monkey and mouse. Mutation Taster8 and SIFT9 programs predict
this single amino acid change to be disease-causing, whereas a
third in silico program, PolyPhen,10 predicts this variant to be
benign. The presence of a missense mutation as opposed to a more
severe truncating mutation, and the substitution of an amino acid
with similar polarity and hydrophobicity are consistent with the
milder GEFS+ phenotype seen in this family, as previously
reported.7 We conclude that with the current evidence and in
particular the segregation analysis along with a change to the
highly conserved valine, it is likely that the c.4135G > T
[p.Val1397Leu] variant is responsible for this seizure-related
phenotype in this family.
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